[go: up one dir, main page]

WO2002097031A3 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2002097031A3
WO2002097031A3 PCT/US2002/010056 US0210056W WO02097031A3 WO 2002097031 A3 WO2002097031 A3 WO 2002097031A3 US 0210056 W US0210056 W US 0210056W WO 02097031 A3 WO02097031 A3 WO 02097031A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/010056
Other languages
English (en)
Other versions
WO2002097031A2 (fr
Inventor
Abel Daffo
Anissa Lee Jones
Alanna-Phung B Tran
Christopher R Dahl
Darryl Gietzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2002344208A priority Critical patent/AU2002344208A1/en
Priority to CA002442705A priority patent/CA2442705A1/fr
Publication of WO2002097031A2 publication Critical patent/WO2002097031A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002097031A3 publication Critical patent/WO2002097031A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp). L'invention concerne par ailleurs des polypeptides (DITHP) codés par dithp, l'utilisation de dithp, ou de compléments, d'oligonucléotides, ou de fragments de celle-ci dans des méthodes diagnostiques. De plus, l'invention concerne des vecteurs et des cellules hôtes contenant dithp pour l'expression de DITHP. L'invention concerne en outre l'utilisation de DITHP isolée et purifiée pour induire des anticorps et cribler des banques de composés ainsi que l'utilisation des anticorps anti-DITHP dans des méthodes d'agnostiques. L'invention concerne enfin des micro-réseaux contenant dithp et des méthodes d'utilisation correspondantes.
PCT/US2002/010056 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques Ceased WO2002097031A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002344208A AU2002344208A1 (en) 2001-03-28 2002-03-27 Molecules for diagnostics and therapeutics
CA002442705A CA2442705A1 (fr) 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US27961901P 2001-03-28 2001-03-28
US60/279,619 2001-03-28
US28006801P 2001-03-29 2001-03-29
US28006701P 2001-03-29 2001-03-29
US60,280,068 2001-03-29
US60/280,067 2001-03-29
US29128001P 2001-05-16 2001-05-16
US60/291,280 2001-05-16
US29182901P 2001-05-17 2001-05-17
US29184901P 2001-05-17 2001-05-17
US60,291,829 2001-05-17
US60/291,849 2001-05-17
US29942801P 2001-06-19 2001-06-19
US60,299,428 2001-06-19
US29977601P 2001-06-20 2001-06-20
US30000101P 2001-06-20 2001-06-20
US60/300,001 2001-06-20
US60/299,776 2001-06-20

Publications (2)

Publication Number Publication Date
WO2002097031A2 WO2002097031A2 (fr) 2002-12-05
WO2002097031A3 true WO2002097031A3 (fr) 2005-05-12

Family

ID=27578771

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/009944 Ceased WO2002079449A2 (fr) 2001-03-28 2002-03-27 Molecules permettant de detecter et de traiter des maladies
PCT/US2002/010056 Ceased WO2002097031A2 (fr) 2001-03-28 2002-03-27 Molecules utilisees a des fins diagnostiques et therapeutiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009944 Ceased WO2002079449A2 (fr) 2001-03-28 2002-03-27 Molecules permettant de detecter et de traiter des maladies

Country Status (4)

Country Link
EP (1) EP1383894A2 (fr)
AU (2) AU2002344208A1 (fr)
CA (2) CA2447183A1 (fr)
WO (2) WO2002079449A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
WO2002074906A2 (fr) * 2001-03-16 2002-09-26 Eli Lilly And Company Proteines de mammiferes lp et reactifs associes
DE60220621T2 (de) 2001-11-09 2008-03-06 Proteologics, Inc. Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren
US8753822B2 (en) * 2001-12-04 2014-06-17 Wayne State University Neoepitope detection of disease using protein arrays
IL165364A0 (en) * 2002-05-28 2006-01-15 Omrix Biopharmaceuticals Inc Method for obtaining anti-idiotype antibodies
WO2003104427A2 (fr) 2002-06-05 2003-12-18 Case Western Reserve University Methodes et compositions pour detecter des cancers
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
TW200413539A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
WO2004033687A1 (fr) * 2002-10-11 2004-04-22 Yamanouchi Pharmaceutical Co., Ltd. Procede de criblage d'un medicament contre l'insuffisance renale
EP2311870A1 (fr) * 2002-11-26 2011-04-20 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
WO2004061109A1 (fr) * 2002-12-27 2004-07-22 National Institute Of Advanced Industrial Science And Technology Glycosyltransferase, acide nucleique codant ladite glycosyltransferase et methode de test de cancerisation a l'aide dudit acide nucleique
GB0315827D0 (en) * 2003-07-05 2003-08-13 Imp College Innovations Ltd Methods
WO2005117538A2 (fr) * 2004-04-12 2005-12-15 The Trustees Of Columbia University In The City Of New York Procedes et compositions pour inhiber l'interaction entre l'enzyme abad et la proteine a$g(b)
EP1627922A1 (fr) * 2004-08-18 2006-02-22 Sanofi-Aventis Deutschland GmbH Méthode de sélection d'agonistes et d'antagonistes du transporteur de carnitine et son utilisation
GB0423126D0 (en) * 2004-10-18 2004-11-17 Ares Trading Sa Protein
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US8652472B2 (en) 2006-12-05 2014-02-18 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20110250218A1 (en) 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
JP2012508586A (ja) 2008-11-14 2012-04-12 ジェン−プローブ・インコーポレーテッド カンピロバクター属（Ｃａｍｐｙｌｏｂａｃｔｅｒ）核酸を検出するための組成物、キットおよび方法
KR101882523B1 (ko) * 2010-03-26 2018-07-26 트러스티스 오브 다트마우스 칼리지 Ｖｉｓｔａ 조절 ｔ 세포 매개 단백질, ｖｉｓｔａ 결합제 및 그것의 용도
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
SG188497A1 (en) 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
BR112014032276A2 (pt) 2012-06-22 2017-11-28 King S College London construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2884704C (fr) 2012-09-07 2023-04-04 Randolph J. Noelle Modulateurs vista de diagnostic et de traitement de cancer
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
MY182431A (en) 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3154585B1 (fr) 2014-06-11 2022-02-23 Kathy A. Green Utilisation d'antagonistes et d'agonistes vista pour supprimer ou améliorer l'immunité humorale
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
JP7026509B2 (ja) 2015-06-24 2022-02-28 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体およびフラグメント
EP3413910A1 (fr) 2016-02-12 2018-12-19 Janssen Pharmaceutica NV Anticorps anti-vista (b7h5)
US11525000B2 (en) 2016-04-15 2022-12-13 Immunext, Inc. Anti-human VISTA antibodies and use thereof
WO2020006108A2 (fr) * 2018-06-26 2020-01-02 Duke University Récepteurs odorants synthétiques
CN110714017B (zh) * 2019-11-06 2023-09-01 河南师范大学 锦鲤ptps基因、编码蛋白及应用
CN114317732B (zh) * 2021-04-08 2023-08-18 博尔诚（北京）科技有限公司 用于肺癌筛查的组合物及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 12 August 2000 (2000-08-12), BIRREN B. ET AL., XP002985580, Database accession no. AC026828 *
DATABASE GENBANK [online] 12 May 1998 (1998-05-12), LEE G.H. ET AL., XP002985581, Database accession no. OAU94889 *
DATABASE GENBANK [online] 12 May 2000 (2000-05-12), BIRREN B. ET AL., XP002985579, Database accession no. AC036206 *
DATABASE GENBANK [online] 5 August 1998 (1998-08-05), DAVOLI R. ET AL., XP002985582, Database accession no. SSGAPDH *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227008B2 (en) 1999-04-12 2007-06-05 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7306796B2 (en) 1999-04-12 2007-12-11 Agensys, Inc. 13-transmembrane protein expressed in prostate cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途

Also Published As

Publication number Publication date
WO2002079449A2 (fr) 2002-10-10
CA2442705A1 (fr) 2002-12-05
WO2002097031A2 (fr) 2002-12-05
EP1383894A2 (fr) 2004-01-28
CA2447183A1 (fr) 2002-10-10
AU2002338265A1 (en) 2002-10-15
WO2002079449A3 (fr) 2003-03-20
AU2002344208A1 (en) 2002-12-09
AU2002344208A8 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002083876A3 (fr) Molecules secretoires
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002099080A3 (fr) Methodes de clonage d'adn, a faible pourcentage de clones negatifs, a l'aide d'oligonucleotides longs
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2002020756A3 (fr) Molécules sécrétoires
WO2002040715A3 (fr) Molecules permettant la detection et le traitement de maladies
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2005069854A3 (fr) Procedes et materiaux ayant trait a de nouveaux polypeptides et polynucleotides contenant le domaine c1q
WO2003062385A3 (fr) Molecules secretoires
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2001062918A3 (fr) Molecules secretoires
WO2002079473A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002018576A3 (fr) Compositions et methodes associees aux genes specifiques du poumon
WO2001021836A3 (fr) Molecules pour le diagnostic et la therapeutique
WO2000075298A3 (fr) Molecules pour la detection et le traitement de maladies
WO2002057304A3 (fr) Molecules secretrices
WO2003027231A3 (fr) Polynucleotide codant pour une nouvelle proteine d'adaptation, pmn29, contenant le domaine d'homologie avec la pleckstrine et le domaine riche en proline
WO2000004041A3 (fr) Procedes et materiaux associes a de nouveaux polypeptides semblables a cd39

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002751955

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2442705

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002751955

Country of ref document: EP

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP